Clinical study of appropriate length artificial chordae tendineae
implantation in Mitral Valve Replacement for rheumatic heart disease
Abstract
Abstract Background We aimed to investigate the clinical effect of
implantation of artificial chordae tendineae with appropriate length in
Mitral Valve Replacement (MVR) for rheumatic heart disease. Methods The
clinical data of a total of 105 patients with rheumatic mitral stenosis
who underwent MVR in the Second Affiliated Hospital of Nanchang
University from July 2017 to July 2018 were analyzed retrospectively.
According to whether the artificial chordae tendineae were implanted
during the operation, the patients were divided into Mitral Valve
Replacement with artificial chordae tendineae implantation group
(experimental group, n=55) and simple Mitral Valve Replacement group
(control group, n=50).Compared two groups of patients with early
postoperative mortality and complications, postoperative cardiac
structure and left ventricular function changes. Result Compared with
the control group, the ascending aorta occlusion time, cardiopulmonary
bypass time and operation time in the experimental group were slightly
longer than those in the control group, but there was no significant
difference between the two groups (P > 0.05).One patient
died early after operation in the control group and none in the
experimental group. All patients had no complications such as prosthetic
valve dysfunction, peri-valvular leakage and ventricular rupture. There
were significant differences in left ventricular ejection fraction
(LVEF), left ventricular end-diastolic diameter (LVEDD), left
ventricular end-systolic diameter (LVESD) and cardiac function grade
between the two groups at 5 days, 3 months and 1 year after operation.
Conclusion Implantation of artificial chordae tendineae with appropriate
length into MVR in patients with rheumatic heart disease can effectively
maintain left ventricular function, reduce postoperative complications
and improve postoperative quality of life. Keywords Rheumatic heart
disease; Mitral Valve Replacement; Artificial chordae tendineae